What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
Exclusive insights from Ned Milenkovich, PharmD, JD, help parse what pharmacists should be aware of as most favored nation initiatives are agreed upon with the federal government.
Over the past 5 months, a number of pharmaceutical companies have reached agreements with the Trump Administration to voluntarily reduce list prices for key drugs in their pipelines for patients on Medicaid and align with a most favored nation (MFN) drug pricing model for newly launched drugs. These actions could help lower drug prices in the United States for blockbuster treatments such as semaglutide (Ozempic, Wegovy; Novo Nordisk), apixaban (Eliquis; Bristol Myers Squibb/Pfizer Inc), tirzepatide (Mounjaro, Zepbound; Eli Lilly and Company), and others to ones comparable to the often lower prices in other high-income countries.1,2